Abstract: A pipeline pig handling apparatus configured to provide loading and unloading of pipeline pigs and ensure a safe process thereof. The apparatus of the present invention includes a frame wherein the frame is partitioned into a first portion and a second portion. The first portion of the frame houses the drive unit wherein the drive unit includes a drive motor, a power supply, an oil reservoir, a drive ram brace unit and a ram shaft. The drive motor is operably coupled to the ram shaft and configured to provide hydraulic movement thereof. The second portion of the frame houses the plunger chamber wherein the plunger chamber further includes a plunger movably disposed therein. The plunger chamber is contiguously formed with a concentric reducer wherein the concentric reducer has a portion thereof that extends beyond an end plate of the frame and is configured with a pipe clamp.

Abstract: Formation of a sterile connection includes inserting a first aseptic coupling device into a second aseptic coupling device while a locking ring of the first aseptic device is in an indexed initial position, rotating the locking ring to a secured position in which a compressive force is created and in which a first membrane from the first aseptic coupling device and a second membrane from the second aseptic coupling device can removed thereby resulting in a first a first sealing member of the first aseptic coupling device sealing with a second sealing member of the second aseptic coupling device to form a sterile fluid passageway.

Abstract: Formation of a sterile connection includes inserting a first aseptic coupling device into a second aseptic coupling device while a locking ring of the first aseptic device is in an indexed initial position, rotating the locking ring to a secured position in which a compressive force is created and in which a first membrane from the first aseptic coupling device and a second membrane from the second aseptic coupling device can removed thereby resulting in a first a first sealing member of the first aseptic coupling device sealing with a second sealing member of the second aseptic coupling device to form a sterile fluid passageway.

Abstract: Formation of a sterile connection includes inserting a first aseptic coupling device into a second aseptic coupling device while a locking ring of the first aseptic device is in an indexed initial position, rotating the locking ring to a secured position in which a compressive force is created and in which a first membrane from the first aseptic coupling device and a second membrane from the second aseptic coupling device can removed thereby resulting in a first a first sealing member of the first aseptic coupling device sealing with a second sealing member of the second aseptic coupling device to form a sterile fluid passageway.

Abstract: The present invention provides methods for defining a disease or condition with a wide range of etiologies based on clustering of genes belong to the same biological pathway and observed frequencies or prevalence of various patient factors assessed in a given patient population, including motor and non-motor symptoms, neuropathology, age of onset, genetics, and involvement of peripheral autonomic system, including the enteric nervous system of the gastrointestinal (GI) system. Also disclosed herein are methods and kits for early diagnosis and treatment of subjects for multisystem Lewy body disease (MLBD), including Parkinson's disease, and/or one or more GI conditions that indicate a propensity for MLBD.

Abstract: Formation of a sterile connection includes inserting a first aseptic coupling device into a second aseptic coupling device while a locking ring of the first aseptic device is in an indexed initial position, rotating the locking ring to a secured position in which a compressive force is created and in which a first membrane from the first aseptic coupling device and a second membrane from the second aseptic coupling device can removed thereby resulting in a first a first sealing member of the first aseptic coupling device sealing with a second sealing member of the second aseptic coupling device to form a sterile fluid passageway.

Abstract: Formation of a sterile connection includes inserting a first aseptic coupling device into a second aseptic coupling device while a locking ring of the first aseptic device is in an indexed initial position, rotating the locking ring to a secured position in which a compressive force is created and in which a first membrane from the first aseptic coupling device and a second membrane from the second aseptic coupling device can removed thereby resulting in a first a first sealing member of the first aseptic coupling device sealing with a second sealing member of the second aseptic coupling device to form a sterile fluid passageway.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: A fluid manifold includes: a main body defining a fluid pathway; and a plurality of ports coupled to the main body and in fluid communication with the fluid pathway, wherein each of the ports includes a first termination. Each first termination is configured to be coupled to a respective fluid coupler in a fluid tight manner using one or more of the following techniques: overmolding; sonic welding; spin welding; snap joints; heat welding; plastic welding; solvent bonding; vibration welding; and induction welding.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to said novel phosphorylation sites, and laboratory and clinical uses thereof.

Abstract: A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.

Abstract: A method for identifying a compound expected to be useful in modulating, for example inhibiting, LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the protein kinase activity of a LRRK2 polypeptide on a substrate polypeptide and (2) selecting a compound which modulates, for example inhibits, the said LRRK2 polypeptide protein kinase activity, wherein the substrate polypeptide comprises the sequence (W/F/R/K)(W/F/R/K)(R/K)(F/W/H/R)(Y/W/R)(S/T)(L/V/I) (R/K)(R/K)(A/Y) or (W/R)(X)(X)(F/Y/H/T)(Y/W/R)(T)(X)(R/T)(R)(X), where X represents any amino acid. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. The substrate polypeptide may consist or comprise the sequence RLGWWRFYTLRRARQGNTKQ.

Abstract: A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.

Abstract: A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.

Abstract: A method for identifying a compound expected to be useful in modulating a LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a LRRK2 polypeptide on a substrate Ezrin/Radixin/moesin (ERM) family polypeptide and (2) selecting a compound which modulates the LRRK2 polypeptide protein kinase activity. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. A catalytically active fragment of LRRK2 is identified, requiring the GTPase, COR and kinase domains as well as the WD_40-like motif and C-terminal tail.

Abstract: A method for identifying a compound expected to be useful in modulating, for example inhibiting, LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the protein kinase activity of a LRRK2 polypeptide on a substrate polypeptide and (2) selecting a compound which modulates, for example inhibits, the said LRRK2 polypeptide protein kinase activity, wherein the substrate polypeptide comprises the sequence (W/F/R/K)(W/F/R/K)(R/K)(F/W/H/R)(Y/W/R)(S/T)(L/V/I) (R/K)(R/K)(A/Y) or (W/R)(X)(X)(F/Y/H/T)(Y/W/R)(T)(X)(R/T)(R)(X), where X represents any amino acid. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. The substrate polypeptide may consist or comprise the sequence RLGWWRFYTLRRARQGNTKQ.

Abstract: A female coupling includes a body defining a fluid pathway therethrough, and a slot extending transversely with respect to the fluid pathway, and a latch positioned in the slot to move between locked and unlocked positions. One or both of the body and the latch are molded of a material including a reduced friction additive.